Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

Learn more about the discovery of insulin and the controversy this life-saving medicine sparked.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

More than 1,300 Florida A&M University students turned their tassels during the spring commencement at the Alfred Lawson Jr.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Lilly, which has its headquarters in Indianapolis, first announced that it would be seeking approval from Limerick City and ...

A new nonstop connection between Indianapolis and Dublin, Ireland, will begin flying out of the Indianapolis International ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...